Record: 141

04/27/2017

Daily Note

Pages: 3

Discontinuation of Research Coverage

Provider: Feltl & Company

Price: 10.00

Record: 142

04/27/2017

Daily Note

Pages: 5

Onpro Kit Exits 1Q17 with 50% Share of Amgen''s Neulasta Franchise and Continues to Grow

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 143

04/19/2017

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (March): Share of Onpro Recovers; Now For the First Time Represents Over 50% of Neulasta Franchise

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 144

04/17/2017

Daily Note

Pages: 41

1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Record: 145

03/27/2017

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (February): Share of Onpro Slips Slightly in February

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 146

02/28/2017

Company Report

Pages: 10

Revenue strong in Q4, guidance inline with expectations - maintain HOLD, $41.50PT

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Record: 147

02/28/2017

Company Report

Pages: 9

PODD Delivers a Solid Quarter and Issues Healthy Outlook; Reiterate OUTPERFORM and Raising PT to $50

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Record: 148

02/27/2017

Company Report

Pages: 8

Insulin Pump Project: Historical survey of ~7,000 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Record: 149

02/22/2017

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (January): Normalizing for the Expected Semi-Annual Spike in Neulasta Scripts, Share of Onpro at Over 50%

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 150

02/03/2017

Daily Note

Pages: 4

Update on Neulasta Onpro Kit From Amgen''s EPS Call; Share of Neulasta Franchise Expected To Continue Growing

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 151

01/24/2017

Industry Report

Pages: 6

Medical Devices: Diabetes Market Implications from JNJ''s Potential Exit

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Record: 152

01/13/2017

Industry Report

Pages: 6

CMS to Reimburse DXCM''s G5; Positive for DXCM, PODD, TNDM; Negative for MDT

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Record: 153

12/21/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker (November): Latest RX Data Continue To Point Toward 50% Share of Neulasta by Yearend; Reit. OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 154

11/23/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker: October Results In Line; On Track For 50% Share of Neulasta by Yearend; Reit. OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 155

11/17/2016

Daily Note

Pages: 9

Analyst Day Highlights a Solid Foundation From Which to Drive Robust Growth; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Record: 156

11/04/2016

Company Report

Pages: 9

Another "beat-and-raise", strength across the board - reiterate BUY, target to $41.50

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Record: 157

11/04/2016

Company Report

Pages: 8

3Q16 Results - A Ray of Sunshine in an Otherwise Gloomy Diabetes Quarter; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Record: 158

11/01/2016

Company Report

Pages: 7

Insulin Pump Project: Historical survey of ~6,700 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Record: 159

10/27/2016

Daily Note

Pages: 5

Amgen''s Reported Onpro Kit Share In Line with Our Analysis and On Track to Capture 50% of Neulasta Franchise Exiting 2016; Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Record: 160

10/19/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker: September Resumes Onpro''s Growing Share of the Amgen''s Neulasta Franchise;Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00